RT Journal Article
SR Electronic
T1 4CPS-175 Evolution of antimicrobial consumption in a trauma intensive care unit using defined daily doses per 100 occupied bed days
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP A130
OP A130
DO 10.1136/ejhpharm-2020-eahpconf.276
VO 27
IS Suppl 1
A1 Gómez-Ganda, L
A1 Lalueza-Broto, P
A1 Arévalo-Bernabé, ÁG
A1 Rey-Pérez, A
A1 Baena-Caparrós, J
A1 Domenech-Moral, L
A1 Baguena-Martínez, M
YR 2020
UL http://ejhp.bmj.com/content/27/Suppl_1/A130.1.abstract
AB Background and importance Microbial resistance to antimicrobial treatment constitutes a public health problem, principally in the hospital environment.Aim and objectives To evaluate the evolution of antimicrobial consumption in a trauma intensive care unit (ICUt) using defined daily doses per 100 occupied bed days (DDD/100 OBD).Material and methods A retrospective study was conducted at a third level hospital including all patients admitted to the ICUt from January 2016 to December 2018. We collected biodemographic and clinical data of patients, and annual DDD/100 OBD and DDD/100 OBD for each antimicrobial drug. We used DDD established by the WHO’s International Working Group for Drug Statistics Methodology of Norway.Results A total of 1206 patients (68.0% men) were included with a median age of 54±19 years. The main diagnosis was trauma (74.3%). Biodemographic and clinical data were similar for the 3 years.In 2016, DDD/100 OBD were 131.12: DDD/100 OBD for penicillins were 60.00 (amoxicillin/clavulanate 33.90, piperacillin/tazobactam 12.39), cephalosporins 13.95, fluoroquinolones 3.70, carbapenems 1532 (meropenem 14.34), aminoglycosides 3.15, daptomycin 3.36, linezolid 2.38, glycopeptides 4.11 and antifungals 7.34 (fluconazole 6,48).In 2017, DDD/100 OBD were 137.62: DDD/100 OBD for penicillins were 54.77 (amoxicillin/clavulanate 35.03, piperacillin/tazobactam 8.37), cephalosporins 16.14, fluoroquinolones 9.42, carbapenems 16.00 (meropenem 15.36), aminoglycosides 2.86, daptomycin 4.68, linezolid 3.27, glycopeptides 3.05 and antifungals 3.69 (fluconazole 2.76).In 2018, DDD/100 OBD were 133.09: DDD/100 OBD for penicillins were 60.42 (amoxicillin/clavulanate 39.81, piperacillin/tazobactam 6.76), cephalosporins 14.37, fluoroquinolones 7.07, carbapenems 15.03 (meropenem 13.08), aminoglycosides 5.69, daptomycin 2.35, linezolid 3.32, glycopeptides 3.85 and antifungals 3.74 (fluconazole 3.35).From 2016 to 2018, the results showed:Important reduction in DDD/100 OBD for piperacillin/tazobactam (−45.46%) but an increase in DDD/100 OBD for amoxicillin/clavulanate (+17.42%).Stable use of cephalosporins, with a minimum consumption of ceftolozane/tazobactam (<1.5%).Stable consumption of carbapenems, with meropenem being the most prescribed (>87%) and reduction in the use of imipenem/cilastatin (−32.51%).Reduction in prescription of antifungals (−49.02%), with fluconazole the most used (>74%).Conclusion and relevance Reduction of piperacillin/tazobactam use with an increase in amoxicillin/clavulanate prescriptions showed a decrease in extended spectrum penicillin consumption and could demonstrate the appropriateness of empirical therapy. Low ceftolozane/tazobactam prescriptions demonstrated controlled prescription of restricted use cephalosporins. Minimum imipenem/cilastatin use could be in relation to its neurotoxic effects. The results indicate an adequate use of antifungals.References and/or acknowledgements No conflict of interest.